Log in

NASDAQ:PULM - Pulmatrix Stock Price, Forecast & News

$0.85
-0.01 (-1.16 %)
(As of 12/15/2019 03:38 PM ET)
Today's Range
$0.83
Now: $0.85
$0.87
50-Day Range
$0.69
MA: $0.81
$0.88
52-Week Range
$0.61
Now: $0.85
$3.80
Volume112,748 shs
Average Volume146,805 shs
Market Capitalization$17.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$2.32 per share

Profitability

Net Income$-20,560,000.00

Miscellaneous

Employees22
Market Cap$17.00 million
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.


Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix's stock reverse split before market open on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) released its earnings results on Friday, November, 1st. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.16. The biotechnology company had revenue of $1.41 million for the quarter. View Pulmatrix's Earnings History.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Pulmatrix.

What price target have analysts set for PULM?

1 brokerages have issued 1-year price targets for Pulmatrix's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Pulmatrix's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,076.3% from the stock's current price. View Analyst Price Targets for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

Headlines about PULM stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pulmatrix earned a news impact score of -1.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Pulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a decrease in short interest in November. As of November 15th, there was short interest totalling 253,100 shares, a decrease of 30.9% from the October 31st total of 366,400 shares. Based on an average trading volume of 157,600 shares, the short-interest ratio is presently 1.6 days. Currently, 1.3% of the shares of the stock are sold short. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include Neovasc (NVCN), Verastem (VSTM), Cronos Group (CRON), Evoke Pharma (EVOK), Novavax (NVAX), Cara Therapeutics (CARA), Rexahn Pharmaceuticals (REXN), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP) and ZIOPHARM Oncology (ZIOP).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $0.85.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $17.00 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.View Additional Information About Pulmatrix.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com/.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel